Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.

This review discusses the various treatment options for male and female pattern hair loss and provides no new clinical results; the authors outline the most effective strategies based on existing evidence.

This article reviews the historical developments in understanding and treating male pattern hair loss, emphasizing the role of dihydrotestosterone and 5α-reductase inhibitors, but reports no new clinical findings.

In this study, administering 5alpha-reductase inhibitors reduced dihydrotestosterone levels and was associated with mild, reversible decreases in semen parameters in healthy men.

This article discusses the long-standing use and safety of opioids in anaesthesia, noting that respiratory depression is a manageable side effect due to the availability of opioid antagonists.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

This study found that oral finasteride 1 mg/day promotes hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss over two years.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This article discusses treatment options for androgenetic alopecia, noting that medical interventions like finasteride and minoxidil can halt and partially reverse hair loss in mild to moderate cases, especially when combined with surgery.

This review critically examines the current medical management strategies for BPH/LUTS and reports no new experimental results.

This study found that in captive mouflon rams, reproductive and physical maturation, marked by changes in hormone levels and physical attributes, progresses gradually across their life span, with sexual maturity tied closely to physical maturity.

This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.

This article discusses the potential effects of exogenous testosterone, highlighting that its impact on prostate cancer progression, cardiovascular health, and behavior remains uncertain and needs further investigation.

This study found that oral finasteride was more effective than 5% topical minoxidil in treating mild to severe androgenetic alopecia in males, with both treatments deemed effective and safe over 12 months.

This article reviews the coordination of the hypothalamic-pituitary-gonadal axis, male fertility, and therapies for hypogonadism, but reports no new clinical findings.

This study found that untreated men with coeliac disease exhibited androgen resistance, potentially linked to sexual dysfunction, which improved as intestinal health improved, a pattern not observed in other chronic illnesses.

Hormonal treatment in transgender women reduces semen quality, but stopping treatment may improve it.

This review discusses phytotherapy options for managing benign prostatic hyperplasia, noting some herbal agents show promise in trials for mild-moderate symptoms but more evidence is needed for others.

This review discusses various substances that can impact male fertility and stresses that products should be confirmed 'sperm-safe' through rigorous testing, not assumptions; it reports no new study results.

This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.

Finasteride reduces hair loss and treats BPH without major hormone changes, but may cause sexual dysfunction.

This review explores the impact of various medications on male fertility, highlighting reversible negative effects from methotrexate, finasteride, and ketoconazole, while reporting no adverse fertility effects for oral retinoids and certain immunosuppressants.

This article reviews treatment options for androgenetic alopecia and suggests that therapy should be personalized and targeted at various pathophysiological aspects, but reports no new clinical findings.

This study found that discontinuing finasteride led to a significant increase in sperm counts for most men with reduced fertility, though hormone levels and other semen parameters remained unchanged.

This review discusses the pathogenesis and treatment of androgenetic alopecia, highlighting genome associations and newer topical formulations, but reports no new clinical results.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

In this study, 68% of patients treated with finasteride showed improved hair growth in male androgenetic alopecia, compared to 38% with Serenoa repens, indicating finasteride's superior efficacy.

This review assesses the current literature on COVID-19's effects on male sexual and reproductive health, highlighting significant research gaps and providing guidance for patient counseling.

In this study, the authors concluded that COVID-19 may not cause direct long-term harm to testicular function, but temporary indirect effects could occur, suggesting a possible delay in pursuing parenthood post-recovery.

This study found that finasteride 1 mg was effective in improving androgenetic alopecia over 10 years in men, particularly those older than 30, with some reporting beneficial results even after 5 years.